Table 4.
Univariate And Multivariate Analysis Of Prognostics Factors Affecting PFS For Two Treatment Cohorts
| Variables | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| Numbers | HR | P value | HR | P value | ||
| Sex (Male vs Female) | 114/11 | 0.864(0.449–1.662) | 0.661 | – | – | |
| Age (≥56 vs <56) | 64/61 | 0.780(0.529–1.148) | 0.208 | – | – | |
| AFP level (≥400 ng/mL vs <400 ng/mL) | 65/60 | 0.986(0.669–1.455) | 0.945 | – | – | |
| HBV (Present vs Absent) | 112/13 | 1.013(0.542–1.895) | 0.968 | – | – | |
| Child Pugh Class (B vs A) | 14/111 | 1.112(0.607–2.038) | 0.731 | – | – | |
| Tumor size (≥5 cm vs <5 cm) | 75/50 | 1.408(0.941–2.106) | 0.096 | – | – | |
| Number of lesions (Multiple vs Single) | 108/17 | 2.038(1.083–3.834) | 0.027 | – | – | |
| PVTT (Present vs Absent) | 40/85 | 0.971(0.637–1.482) | 0.892 | – | – | |
| Distant metastasis (Present vs Absent) | 71/54 | 0.945(0.639–1.398) | 0.776 | – | – | |
| Number of Previous TACE (>2 VS ≤2) | 29/96 | 0.714(0.444–1.146) | 0.163 | |||
| Treatments (TACE-apatinib vs TACE) | 42/83 | 0.348(0.223–0.544) | <0.001 | 0.348(0.223–0.544) | <0.001 | |
Notes: The treatment was the only independent prognostic factor of PFS in this study.
Abbreviations: PFS, progression-free survival; AFP, alpha-fetoprotein; HBV, Hepatitis B Virus; PVTT, portal vein tumor thrombus; BCLC, Barcelona Clinic Liver Cancer; TACE, transcatheter arterial chemoembolization.